Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Andrew H who wrote (9925)	10/21/1997 3:57:00 PM
From: squetch	Read Replies (1) \| Respond to of 32384

One possibility(to be blown away by all) is the fusion protein mentioned here. lilly.com It is currently in PIII for CTCL. LLY is codeveloping w/ SRGN so I don't know how plausible this is plus I don't think this make LGND profitable by '99. Having said that kinda cool technology. >>The fusion protein seeks out only cells w/ specific receptors on their surface. The targeting ligand enables the fusion protein to bind to those receptors. The molecular syringe injects the cytotoxic fragment into the targeted cell. Once internalized, the cytotoxic fragment destroys the cell.<< This fusion protein doesn't fit all the criteria. Your guess.